» Articles » PMID: 24993857

TLR9 and BAFF: Their Expression in Patients with IgA Nephropathy

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2014 Jul 5
PMID 24993857
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Since it was first described in 1968, immunoglobulin (Ig)A nephropathy (IgAN) has become the most commonly diagnosed form of primary glomerular disease worldwide. A number of reports have shown that toll‑like receptor 9 (TLR9) and B‑cell activating factor (BAFF) may be associated with IgAN; however, sufficient evidence has not yet to be delivered. In the present study, serum levels of BAFF as well as TLR9 mRNA and protein levels in peripheral blood mononuclear cells (PBMCs) were assessed. Expression of TLR9 mRNA in PBMCs was examined by quantitative polymerase chain reaction and the TLR9 protein was determined by western blot analysis. The levels of serum BAFF and IgA1 were determined by specific ELISA. Serum levels of BAFF and IgA1 as well as levels of TLR9 mRNA and protein in PMBCs were significantly higher in patients with IgAN compared with patients with minimal glomerular abnormalities (P<0.05, P<0.01, P<0.01 and P<0.01, respectively) and normal controls (P<0.01, P<0.01, P<0.05 and P<0.01, respectively). A correlation and regression analysis was performed to determine the pathogenesis of IgAN. In patients with IgAN, serum levels of BAFF were positively correlated with IgA1 levels (rp, 0.515; P<0.01) and mesangial IgA deposition density (rp, 0.746; P<0.01). Expression levels of TLR9 protein in PBMCs of IgAN patients were positively correlated with levels of serum BAFF (rp, 0.444; P<0.05) and IgA1 (rp, 0.633; P<0.01). These results suggested that overexpression of TLR9 mRNA and protein in PBMCs and elevated levels of serum BAFF may be associated with overexpression of serum IgA1, and, furthermore, may have a role in the development of IgAN.

Citing Articles

The Latest Progress in the Application of Telitacicept in Autoimmune Diseases.

Liu B, Zhao Y, Liu D, Li X, Ma Z, Yang Q Drug Des Devel Ther. 2024; 18():5811-5825.

PMID: 39664967 PMC: 11633291. DOI: 10.2147/DDDT.S493923.


Immunoglobulin A Antibodies: From Protection to Harmful Roles.

Gleeson P, Camara N, Launay P, Lehuen A, Monteiro R Immunol Rev. 2024; 328(1):171-191.

PMID: 39578936 PMC: 11659943. DOI: 10.1111/imr.13424.


Lessons from IgA Nephropathy Models.

Kano T, Suzuki H, Makita Y, Nihei Y, Fukao Y, Nakayama M Int J Mol Sci. 2024; 25(21).

PMID: 39519036 PMC: 11546737. DOI: 10.3390/ijms252111484.


IgA Nephropathy: Emerging Mechanisms of Disease.

Roberts L, Williams C, Oni L, Barratt J, Selvaskandan H Indian J Nephrol. 2024; 34(4):297-309.

PMID: 39156850 PMC: 11326799. DOI: 10.25259/ijn_425_23.


Successful pregnancy in a patient with IgA nephropathy treated with telitacicept: a case report.

Du X, Tian G, Lu X BMC Pregnancy Childbirth. 2024; 24(1):432.

PMID: 38886682 PMC: 11181617. DOI: 10.1186/s12884-024-06632-7.